Efficacy and Toxicity of Doxorubicin/Cyclophosphamide Maintenance Therapy in Dogs with Multicentric Lymphosarcoma
Authors:
- 1 September 1991
- journal article
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 5 (5) , 259-262
Abstract
Abstarct: Doxorubicin/cyclophosphamide were evaluated as maintenance drugs for dogs with multicentric lymphosarcoma (n = 28). Median remission time of all dogs was 173 days. Remission duration was shorter, however, in dogs with stage IV/V disease, in dogs with pretreatment hypoalbuminemia, and in dogs that had received glucocorticoids before initiation of chemotherapy (P < 0.04). Nineteen dogs were evaluable for toxicity. Dose-limiting gastrointestinal toxicosis was observed in three dogs, neutropenia was observed in three dogs, and cardiomyopathy was observed in three dogs. The doxorubicin/cyclophosphamide protocol described in this report is safe and effective in treating canine multicentric lymphosarcoma. Clinical stage, pretreatment steroid therapy, and hypoalbuminemia are prognostic factors for response to this protocolKeywords
This publication has 5 references indexed in Scilit:
- Prevalence of leukemic blood and bone marrow in dogs with multicentric lymphomaJournal of the American Veterinary Medical Association, 1989
- Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog: 147 cases (1978-1981)Journal of the American Veterinary Medical Association, 1987
- Glucocorticoid Receptors and Glucocorticoid Resistance in Human Leukemia in Vivo and in Vitro1986
- Histologic classification as an indication of therapeutic response in malignant lymphoma of dogsJournal of the American Veterinary Medical Association, 1984
- Cyclic Combination Chemotherapy of Canine LymphosarcomaJournal of the American Veterinary Medical Association, 1981